These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 9681851)

  • 1. Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations.
    Takahashi M; Asai N; Iwashita T; Murakami H; Ito S
    J Intern Med; 1998 Jun; 243(6):509-13. PubMed ID: 9681851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.
    Ito S; Iwashita T; Asai N; Murakami H; Iwata Y; Sobue G; Takahashi M
    Cancer Res; 1997 Jul; 57(14):2870-2. PubMed ID: 9230192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A.
    Landsvater RM; Jansen RP; Hofstra RM; Buys CH; Lips CJ; Ploos van Amstel HK
    Hum Genet; 1996 Jan; 97(1):11-4. PubMed ID: 8557249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
    Sansó G; Domené HM; Iorcansky S; Barontini M
    Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [From gene to disease; from the RET gene to multiple endocrine neoplasia types 2A and 2B, sporadic and familial medullary thyroid carcinoma, Hirschsprung disease and papillary thyroid carcinoma].
    Hofstra RM; van der Luijt RB; Lips CJ
    Ned Tijdschr Geneeskd; 2001 Nov; 145(46):2217-21. PubMed ID: 11757244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins.
    Asai N; Murakami H; Iwashita T; Takahashi M
    J Biol Chem; 1996 Jul; 271(30):17644-9. PubMed ID: 8663426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
    Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
    J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [One gene--four diseases: on the importance of mutations in the ret gene in MEN 2A, MEN 2B, Hirschsprung disease and medullary thyroid carcinoma].
    Fehmann HC; Göke B
    Z Gastroenterol; 1994 Jul; 32(7):416-7. PubMed ID: 7975780
    [No Abstract]   [Full Text] [Related]  

  • 10. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
    Marsh DJ; Mulligan LM; Eng C
    Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET activation by germline MEN2A and MEN2B mutations.
    Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
    Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
    Kambouris M; Jackson CE; Feldman GL
    Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.
    Kawai K; Iwashita T; Murakami H; Hiraiwa N; Yoshiki A; Kusakabe M; Ono K; Iida K; Nakayama A; Takahashi M
    Cancer Res; 2000 Sep; 60(18):5254-60. PubMed ID: 11016655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RET proto-oncogene mutations in French MEN 2A and FMTC families.
    Schuffenecker I; Billaud M; Calender A; Chambe B; Ginet N; Calmettes C; Modigliani E; Lenoir GM
    Hum Mol Genet; 1994 Nov; 3(11):1939-43. PubMed ID: 7874109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.
    Zedenius J; Wallin G; Hamberger B; Nordenskjöld M; Weber G; Larsson C
    Hum Mol Genet; 1994 Aug; 3(8):1259-62. PubMed ID: 7987299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RET oncogene mutations in medullary thyroid carcinoma in Mexican families.
    González B; Salcedo M; Medrano ME; Mantilla A; Quiñónez G; Benítez-Bribiesca L; Rodríguez-Cuevas S; Cabrera L; de León B; Altamirano N; Tapia J; Dawson B
    Arch Med Res; 2003; 34(1):41-9. PubMed ID: 12604374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.
    Eng C; Clayton D; Schuffenecker I; Lenoir G; Cote G; Gagel RF; van Amstel HK; Lips CJ; Nishisho I; Takai SI; Marsh DJ; Robinson BG; Frank-Raue K; Raue F; Xue F; Noll WW; Romei C; Pacini F; Fink M; Niederle B; Zedenius J; Nordenskjöld M; Komminoth P; Hendy GN; Mulligan LM
    JAMA; 1996 Nov; 276(19):1575-9. PubMed ID: 8918855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
    Fink M; Weinhüsel A; Niederle B; Haas OA
    Int J Cancer; 1996 Aug; 69(4):312-6. PubMed ID: 8797874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.
    Iwashita T; Asai N; Murakami H; Matsuyama M; Takahashi M
    Oncogene; 1996 Feb; 12(3):481-7. PubMed ID: 8637703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma.
    Iwashita T; Kato M; Murakami H; Asai N; Ishiguro Y; Ito S; Iwata Y; Kawai K; Asai M; Kurokawa K; Kajita H; Takahashi M
    Oncogene; 1999 Jul; 18(26):3919-22. PubMed ID: 10445857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.